FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hans Wedel

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Sweden

Procedures

Double-Blind Method

Co-author Network

Publications

TOP 3
Lena Carlsson; Peter Jacobson; Hans Lönroth; Cristina Maglio; Ingmar Näslund; Markku Peltonen; Carlo Pirazzi; Stefano Romeo; Kajsa Sjöholm; Elisabeth Sjöström; Sofie Ahlin; Åsa Anveden; Claude Bouchard; Björn Carlsson; Per-Arne Svensson; Hans Wedel; Lars Sjöström
Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects.
Keld Vægter; Rolf Wahlström; Hans Wedel; Kurt Svärdsudd
Effect of mailed feedback on drug prescribing profiles in general practice: a seven-year longitudinal study in Storstrøm County, Denmark.
Neil R Poulter; Joanna E Dobson; Peter S Sever; Björn Dahlöf; Hans Wedel; Norm R C Campbell
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hans Wedel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Lena Carlsson; Peter Jacobson; Hans Lönroth; Cristina Maglio; Ingmar Näslund; Markku Peltonen; Carlo Pirazzi; Stefano Romeo; Kajsa Sjöholm; Elisabeth Sjöström; Sofie Ahlin; Åsa Anveden; Claude Bouchard; Björn Carlsson; Per-Arne Svensson; Hans Wedel; Lars Sjöström
Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects.
The New England journal of medicine 2012;367(8):695-704.
2010: Keld Vægter; Rolf Wahlström; Hans Wedel; Kurt Svärdsudd
Effect of mailed feedback on drug prescribing profiles in general practice: a seven-year longitudinal study in Storstrøm County, Denmark.
Upsala journal of medical sciences 2010;115(4):238-44.
2009: Neil R Poulter; Joanna E Dobson; Peter S Sever; Björn Dahlöf; Hans Wedel; Norm R C Campbell
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Journal of the American College of Cardiology 2009;54(13):1154-61.
2009: Lars Sjöström; Anders Gummesson; Carl David Sjöström; Kristina Narbro; Markku Peltonen; Hans Wedel; Calle Bengtsson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Peter Jacobson; Kristjan Karason; Jan Karlsson; Bo Larsson; Anna Karin Lindroos; Hans Lönroth; Ingmar Näslund; Torsten Olbers; Kaj Stenlöf; Jarl S Torgerson; Lena Carlsson
Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial.
The lancet oncology 2009;10(7):653-62.
2009: Peter S Sever; Neil R Poulter; Stylianos E Mastorantonakis; Choon-Lan Chang; Bjorn Dahlof; Hans Wedel
Coronary heart disease benefits from blood pressure and lipid-lowering.
International journal of cardiology 2009;135(2):218-22.
2009: Mats Gulliksson; Hans Wedel; Max Köster; Kurt Svärdsudd
Hazard function and secular trends in the risk of recurrent acute myocardial infarction: 30 years of follow-up of more than 775,000 incidents.
Circulation. Cardiovascular quality and outcomes 2009;2(3):178-85.
2009: Peter S Sever; Neil R Poulter; Bjorn Dahlof; Hans Wedel
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Journal of hypertension 2009;27(5):947-54.
2009: Sverre E Kjeldsen; Richard B Devereux; Darcy A Hille; Paulette A Lyle; Björn Dahlöf; Stevo Julius; Jonathan M Edelman; Steven M Snapinn; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Blood pressure 2009;18(6):348-61.
2009: Thorne Wallman; Hans Wedel; Edward Palmer; Annika Rosengren; Saga Johansson; Henry Eriksson; Kurt Svärdsudd
Sick-leave track record and other potential predictors of a disability pension. A population based study of 8,218 men and women followed for 16 years.
BMC public health 2009;9():104.
2009: Annika Bardel; Mari-Ann Wallander; Hans Wedel; Kurt Svärdsudd
Age-specific symptom prevalence in women 35-64 years old: a population-based study.
BMC public health 2009;9():37.
2008: Neil Chapman; Choon-Lan Chang; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial.
Circulation 2008;118(1):42-8.
2008: Lars Wilhelmsen; Lennart Welin; Kurt Svärdsudd; Hans Wedel; Henry Eriksson; Per O Hansson; Annika Rosengren
Secular changes in cardiovascular risk factors and attack rate of myocardial infarction among men aged 50 in Gothenburg, Sweden. Accurate prediction using risk models.
Journal of internal medicine 2008;263(6):636-43.
2008: Ajay K Gupta; Bjorn Dahlof; Joanna Dobson; Peter S Sever; Hans Wedel; Neil R Poulter
Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.
Diabetes care 2008;31(5):982-8.
2008: Peter S Sever; Neil R Poulter; Bjorn Dahlof; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku S Nieminen; Eoin T O'Brien; Jan Ostergren
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
European heart journal 2008;29(4):499-508.
2007: John Kjekshus; Eduard Apetrei; Vivencio Barrios; Michael Böhm; John G F Cleland; Jan H Cornel; Peter H J M Dunselman; Cândida Fonseca; Assen R Goudev; Peer Grande; Lars Gullestad; Ake Hjalmarson; Jaromir Hradec; András Jánosi; Gabriel Kamenský; Michel Komajda; Jerzy Korewicki; Timo Kuusi; François Mach; Vyacheslav Mareev; john mcmurray; Naresh Ranjith; Maria Schaufelberger; Johan Vanhaecke; Dirk J van Veldhuisen; Finn Waagstein; Hans Wedel; John Wikstrand
Rosuvastatin in older patients with systolic heart failure.
The New England journal of medicine 2007;357(22):2248-61.
2007: Lars Sjöström; Kristina Narbro; Carl David Sjöström; Kristjan Karason; Bo Larsson; Hans Wedel; Theodore C Lystig; Marianne Sullivan; Claude Bouchard; Björn Carlsson; Calle Bengtsson; Sven Dahlgren; Anders Gummesson; Peter Jacobson; Jan Karlsson; Anna Karin Lindroos; Hans Lönroth; Ingmar Näslund; Torsten Olbers; Kaj Stenlöf; Jarl S Torgerson; Göran Agren; Lena Carlsson
Effects of bariatric surgery on mortality in Swedish obese subjects.
The New England journal of medicine 2007;357(8):741-52.
2007: Margaretha Eriksson; Hans Wedel; Mari-Ann Wallander; Ingvar Krakau; Jonas Hugosson; Sture Carlsson; Kurt Svärdsudd
The impact of birth weight on prostate cancer incidence and mortality in a population-based study of men born in 1913 and followed up from 50 to 85 years of age.
The Prostate 2007;67(11):1247-54.
2007: Neil Chapman; Joanna Dobson; Sarah Wilson; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Effect of spironolactone on blood pressure in subjects with resistant hypertension.
Hypertension 2007;49(4):839-45.
2007: Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Katherine E Harris; Hans Ibsen; Sverre E Kjeldsen; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Darcy A Hille; Björn Dahlöf
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Current medical research and opinion 2007;23(2):259-70.
2006: Peter S Sever; Björn Dahlöf; Neil Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminem; Eoin O'Brien; Jan Ostergren
Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
European heart journal 2006;27(24):2982-8.
2006: Dirk J van Veldhuisen; Halfdan Aass; Dia el Allaf; Peter H J M Dunselman; Lars Gullestad; Matti Halinen; John Kjekshus; Lis Ohlsson; Hans Wedel; John Wikstrand
Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study.
European journal of heart failure 2006;8(5):539-46.
2006: Thorne Wallman; Hans Wedel; Saga Johansson; Annika Rosengren; Henry Eriksson; Lennart Welin; Kurt Svärdsudd
The prognosis for individuals on disability retirement. An 18-year mortality follow-up study of 6887 men and women sampled from the general population.
BMC public health 2006;6():103.
2005: Sverre E Kjeldsen; Paulette A Lyle; Andrew M Tershakovec; Richard B Devereux; Suzanne Oparil; Björn Dahlöf; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Hans Wedel
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Expert opinion on emerging drugs 2005;10(4):729-45.
2005: John Kjekshus; Peter H J M Dunselman; Malin Blideskog; Christina Eskilson; Ake Hjalmarson; John V McMurray; Finn Waagstein; Hans Wedel; Peter Wessman; John Wikstrand
A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics.
European journal of heart failure 2005;7(6):1059-69.
2005: Neil R Poulter; Hans Wedel; Björn Dahlöf; Peter S Sever; D Gareth Beevers; Mark Caulfield; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren; Stuart Pocock
Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
Lancet 2005;366(9489):907-13.
2005: Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Lancet 2005;366(9489):895-906.
2005: Eigil Fossum; andreas moan; Sverre E Kjeldsen; Richard B Devereux; Stevo Julius; Steven M Snapinn; Jonathan Edelman; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Björn Dahlöf
The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Journal of the American College of Cardiology 2005;46(5):770-5.
2005: Peter S Sever; Neil R Poulter; Björn Dahlöf; Hans Wedel
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
The American journal of cardiology 2005;96(5A):39F-44F.
2005: Peter S Sever; Neil R Poulter; Björn Dahlöf; Hans Wedel; Rory Collins; Gareth Beevers; Mark Caulfield; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Diabetes care 2005;28(5):1151-7.
2005: Frej Fyhrquist; Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Darcy A Hille; Paulette A Lyle; Jonathan Edelman; Steven M Snapinn; Hans Wedel
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
Hypertension 2005;45(4):580-5.
2005: Sverre E Kjeldsen; Paulette A Lyle; Jorge R Kizer; Björn Dahlöf; Richard B Devereux; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Katherine E Harris; Hans Wedel
The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
Journal of clinical hypertension (Greenwich, Conn.) 2005;7(3):152-8.
2005: Lars Gullestad; John Wikstrand; Prakash Deedwania; Ake Hjalmarson; Kenneth Egstrup; Uri Elkayam; Stephen S Gottlieb; Andrew Rashkow; Hans Wedel; Georgina Bermann; John Kjekshus
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).
Journal of the American College of Cardiology 2005;45(2):252-9.
2005: Jorge R Kizer; Björn Dahlöf; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Kristian Wachtell; Jonathan Edelman; Steven M Snapinn; Katherine E Harris; Richard B Devereux
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Hypertension 2005;45(1):46-52.
2004: Lars Sjöström; Anna Karin Lindroos; Markku Peltonen; Jarl S Torgerson; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Bo Larsson; Kristina Narbro; Carl David Sjöström; Marianne Sullivan; Hans Wedel
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.
The New England journal of medicine 2004;351(26):2683-93.
2004: M Eriksson; Mari-Ann Wallander; Ingvar Krakau; Hans Wedel; Kurt Svärdsudd
The impact of birth weight on coronary heart disease morbidity and mortality in a birth cohort followed up for 85 years: a population-based study of men born in 1913.
Journal of internal medicine 2004;256(6):472-81.
2004: Peter M Okin; Richard B Devereux; Sverker Jern; Sverre E Kjeldsen; Stevo Julius; Markku S Nieminen; Steven M Snapinn; Katherine E Harris; Peter Aurup; Jonathan Edelman; Hans Wedel; Lars H Lindholm; Björn Dahlöf
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
JAMA : the journal of the American Medical Association 2004;292(19):2343-9.
2004: Lars Wilhelmsen; P Held; Hans Wedel
Clinical trials: a summary.
Journal of internal medicine 2004;256(4):284-7.
2004: Peter Johansson; Jack Kutti; Björn Andréasson; Soodabeh Safai-Kutti; Lars Vilén; Hans Wedel; Börje Ridell
Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.
Journal of internal medicine 2004;256(2):161-5.
2004: Henrik M Reims; Sverre E Kjeldsen; W E Brady; Björn Dahlöf; Richard B Devereux; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.
Journal of human hypertension 2004;18(6):381-9.
2004: Aud Høieggen; Michael H Alderman; Sverre E Kjeldsen; Stevo Julius; Richard B Devereux; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Cong Chen; Björn Dahlöf
The impact of serum uric acid on cardiovascular outcomes in the LIFE study.
Kidney international 2004;65(3):1041-9.
2004: M Eriksson; Mari-Ann Wallander; Ingvar Krakau; Hans Wedel; Kurt Svärdsudd
Birth weight and cardiovascular risk factors in a cohort followed until 80 years of age: the study of men born in 1913.
Journal of internal medicine 2004;255(2):236-46.
2004: Henrik M Reims; Suzanne Oparil; Sverre E Kjeldsen; Richard B Devereux; Stevo Julius; William E Brady; Frej Fyhrquist; Hans Ibsen; Lars H Lindholm; Per Omvik; Hans Wedel; Gareth Beevers; Ulf de Faire; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Björn Dahlöf
Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.
Blood pressure 2004;13(6):376-84.
2004: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Drugs 2004;64 Suppl 2():43-60.
2004: Sverker Hasselblom; Börje Ridell; Hans Wedel; Klas Norrby; Monica Sender Baum; Tor Ekman
Testicular lymphoma--a retrospective, population-based, clinical and immunohistochemical study.
Acta oncologica (Stockholm, Sweden) 2004;43(8):758-65.
2003: Kristian Wachtell; Hans Ibsen; Michael H Olsen; Knut Borch-Johnsen; Lars H Lindholm; Carl Erik Mogensen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Peter M Okin; Per Omvik; Suzanne Oparil; Hans Wedel; Steven M Snapinn; Peter Aurup
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Annals of internal medicine 2003;139(11):901-6.
2003: Lars Wilhelmsen; Hans Wedel
[New European diagrams for assessment of cardiovascular risk].
Läkartidningen 2003;100(36):2764-6.
2003: John Wikstrand; Hans Wedel; Jalal K Ghali; Prakash Deedwania; Björn Fagerberg; Sidney Goldstein; Stephen S Gottlieb; Ake Hjalmarson; John Kjekshus; Finn Waagstein
How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF).
Cardiac electrophysiology review 2003;7(3):264-75.
2003: Richard B Devereux; Björn Dahlöf; Sverre E Kjeldsen; Stevo Julius; Peter Aurup; Gareth Beevers; Jonathan Edelman; Ulf de Faire; Frej Fyhrquist; Sigrid Helle Berg; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Hans Wedel
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Annals of internal medicine 2003;139(3):169-77.
2003: P Held; Hans Wedel; Lars Wilhelmsen
Clinical trials: introduction.
Journal of internal medicine 2003;254(2):103-4.
2003: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet 2003;361(9364):1149-58.
2003: Alberto Zanchetti; Lennart Hansson; Denis Clement; Dag Elmfeldt; Stevo Julius; Telma Rosenthal; Bernard Waeber; Hans Wedel
Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers?
Journal of hypertension 2003;21(4):797-804.
2003: Claudia Cabrera; Katarina Wilhelmson; Peter Allebeck; Hans Wedel; Bertil Steen; Lauren Lissner
Cohort differences in obesity-related health indicators among 70-year olds with special reference to gender and education.
European journal of epidemiology 2003;18(9):883-90.
2002: Alberto Zanchetti; Lennart Hansson; Björn Dahlöf; Stevo Julius; Joël Ménard; Ingrid Warnold; Hans Wedel
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk.
Journal of hypertension 2002;20(11):2301-7.
2002: Sverre E Kjeldsen; Björn Dahlöf; Richard B Devereux; Stevo Julius; Peter Aurup; Jonathan Edelman; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Hans Wedel
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
JAMA : the journal of the American Medical Association 2002;288(12):1491-8.
2002: Lars H Lindholm; Hans Ibsen; Knut Borch-Johnsen; Michael H Olsen; Kristian Wachtell; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven M Snapinn
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
Journal of hypertension 2002;20(9):1879-86.
2002: John Wikstrand; Ake Hjalmarson; Finn Waagstein; Björn Fagerberg; Sidney Goldstein; John Kjekshus; Hans Wedel
Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).
Journal of the American College of Cardiology 2002;40(3):491-8.
2002: Alberto Zanchetti; Lennart Hansson; Gastone Leonetti; Karl-Heinz Rahn; Luis M Ruilope; Ingrid Warnold; Hans Wedel
Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.
Journal of hypertension 2002;20(5):1015-22.
2002: Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven M Snapinn
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359(9311):1004-10.
2002: Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359(9311):995-1003.
2002: Lena Bokemark; John Wikstrand; Hans Wedel; Björn Fagerberg
Insulin, insulin propeptides and intima-media thickness in the carotid artery in 58-year-old clinically healthy men. The Atherosclerosis and Insulin Resistance study (AIR).
Diabetic medicine : a journal of the British Diabetic Association 2002;19(2):144-51.
2001: Hans Wedel; D Demets; Prakash Deedwania; Björn Fagerberg; Sidney Goldstein; Stephen S Gottlieb; Ake Hjalmarson; John Kjekshus; Finn Waagstein; John Wikstrand
Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
American heart journal 2001;142(3):502-11.
2001: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
Journal of human hypertension 2001;15 Suppl 1():S11-2.
2001: Lars Wilhelmsen; K Pyörälä; Hans Wedel; T Cook; T Pedersen; J Kjekshus
Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
European heart journal 2001;22(13):1119-27.
2001: Alberto Zanchetti; Lennart Hansson; Björn Dahlöf; Dag Elmfeldt; Sverre E Kjeldsen; Rainer E Kolloch; P Larochelle; Gordon T McInnes; JM Mallion; Luis M Ruilope; Hans Wedel
Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.
Journal of hypertension 2001;19(6):1149-59.
2001: Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.
Journal of hypertension 2001;19(6):1139-47.
2001: Alberto Zanchetti; Lennart Hansson; J Ménard; Gastone Leonetti; K H Rahn; Ingrid Warnold; Hans Wedel
Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study.
Journal of hypertension 2001;19(4):819-25.
2001: Johan Herlitz; Mikael Dellborg; Björn W Karlson; Jonny Lindqvist; Thomas Karlsson; W Sandén; Margareta Sjölin; Hans Wedel
Changes in the use of medications after acute myocardial infarction: possible impact on mortality after myocardial infarction and long-term outcome.
Coronary artery disease 2001;12(1):61-7.
2001: Lena Bokemark; John Wikstrand; Stig Attvall; Johannes Hulthe; Hans Wedel; Björn Fagerberg
Insulin resistance and intima-media thickness in the carotid and femoral arteries of clinically healthy 58-year-old men. The Atherosclerosis and Insulin Resistance Study (AIR).
Journal of internal medicine 2001;249(1):59-67.
2000: Johan Herlitz; Mikael Dellborg; Björn W Karlson; Jonny Lindqvist; Hans Wedel
Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2000;14(6):589-95.
2000: Börje Ridell; Jan Carneskog; Hans Wedel; Lars Vilén; I Høgh Dufva; Ulf-Henrik Mellqvist; N Brywe; Hans Wadenvik; Jack Kutti
Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983-1992.
European journal of haematology 2000;65(4):267-71.
2000: Sverre E Kjeldsen; Björn Dahlöf; R B Devereux; Stevo Julius; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint.
American journal of hypertension 2000;13(8):899-906.
2000: Carl David Sjöström; Markku Peltonen; Hans Wedel; Lars Sjöström
Differentiated long-term effects of intentional weight loss on diabetes and hypertension.
Hypertension 2000;36(1):20-5.
2000: Ake Hjalmarson; Sidney Goldstein; Björn Fagerberg; Hans Wedel; Finn Waagstein; John Kjekshus; John Wikstrand; Dia el Allaf; J Vítovec; J Aldershvile; Matti Halinen; R Dietz; K L Neuhaus; András Jánosi; Gudmundur Thorgeirsson; Peter H J M Dunselman; Lars Gullestad; J Kuch; Johan Herlitz; P Rickenbacher; S Ball; Stephen S Gottlieb; Prakash Deedwania
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
JAMA : the journal of the American Medical Association 2000;283(10):1295-302.
1999: Carl David Sjöström; Lauren Lissner; Hans Wedel; Lars Sjöström
Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study.
Obesity research 1999;7(5):477-84.
1999: Johan Herlitz; Mikael Dellborg; Björn W Karlson; Jonny Lindqvist; W Sandèn; H Svensson; Margareta Sjölin; Hans Wedel
Similar risk reduction of death of extended-release metoprolol once daily and immediate-release metoprolol twice daily during 5 years after myocardial infarction.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1999;13(2):127-35.
1999: Annika Rosengren; Hans Wedel; Lars Wilhelmsen
Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study.
European heart journal 1999;20(4):269-77.
1998: Björn Dahlöf; Richard B Devereux; Stevo Julius; Sverre E Kjeldsen; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Thomas Hedner; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension.
Hypertension 1998;32(6):989-97.
1998: Annika Rosengren; Anders Himmelmann; Lars Wilhelmsen; I Branehög; Hans Wedel
Hypertension and long-term cancer incidence and mortality among Swedish men.
Journal of hypertension 1998;16(7):933-40.
1998: Lennart Hansson; Alberto Zanchetti; S G Carruthers; Björn Dahlöf; Dag Elmfeldt; Stevo Julius; J Ménard; K H Rahn; Hans Wedel; S Westerling
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.
Lancet 1998;351(9118):1755-62.
1997: Björn Dahlöf; R Devereux; Ulf de Faire; Frej Fyhrquist; Thomas Hedner; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
American journal of hypertension 1997;10(7 Pt 1):705-13.